Cargando…

Comparison of SARS-CoV-2 IgM and IgG seroconversion profiles among hospitalized patients in two US cities

The clinical and public health utility of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) serologic testing requires a better understanding of the dynamics of the humoral response to infection. To track seroconversion of IgG and IgM antibodies in patients with SARS-CoV-2 infection and i...

Descripción completa

Detalles Bibliográficos
Autores principales: Orner, Erika P, Rodgers, Mary A, Hock, Karl, Tang, Mei San, Taylor, Russell, Gardiner, Mary, Olivo, Ana, Fox, Amy, Prostko, John, Cloherty, Gavin, Farnsworth, Christopher W.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier Inc. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7759125/
https://www.ncbi.nlm.nih.gov/pubmed/33388575
http://dx.doi.org/10.1016/j.diagmicrobio.2020.115300
_version_ 1783627065725026304
author Orner, Erika P
Rodgers, Mary A
Hock, Karl
Tang, Mei San
Taylor, Russell
Gardiner, Mary
Olivo, Ana
Fox, Amy
Prostko, John
Cloherty, Gavin
Farnsworth, Christopher W.
author_facet Orner, Erika P
Rodgers, Mary A
Hock, Karl
Tang, Mei San
Taylor, Russell
Gardiner, Mary
Olivo, Ana
Fox, Amy
Prostko, John
Cloherty, Gavin
Farnsworth, Christopher W.
author_sort Orner, Erika P
collection PubMed
description The clinical and public health utility of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) serologic testing requires a better understanding of the dynamics of the humoral response to infection. To track seroconversion of IgG and IgM antibodies in patients with SARS-CoV-2 infection and its association with patient and clinical factors and outcomes. Residual patient specimens were analyzed on the Abbott ARCHITECT i2000 instrument using the Abbott SARS-CoV-2 IgG assay and prototype SARS-CoV-2 IgM assay. Age, sex, comorbidities, symptom onset date, mortality, and specimen collection date were obtained from electronic medical records. Three hundred fifty-nine longitudinal samples were collected from 89 hospitalized patients 0 to 82 days postsymptom onset. Of all, 51.7% of the patients developed IgG and IgM antibodies simultaneously; 32.8% seroconverted for IgM before IgG. On average, patients seroconverted for IgG by 8 days and for IgM by 7 days postsymptom onset. All patients achieved IgG seropositivity by 19 days and IgM seropositivity by 17 days. Median time to IgG and IgM seroconversion was prolonged and initial levels of IgG were lower in immunocompromised patients and patients <65 years of age compared to immune competent patients and those ≥65 years of age. Immunocompromised patients also had persistently lower levels of IgM that peaked on day 17.6 and decreased thereafter compared to immune competent patients. IgM seroconversion in patients who died reached significantly higher levels later after symptom onset than in those who recovered. SARS-CoV-2 infected patients have similar time to seroconversion for IgG and IgM. However, differences in immune status and age alter time to seroconversion. These results may help guide serologic testing application in COVID-19 management.
format Online
Article
Text
id pubmed-7759125
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Elsevier Inc.
record_format MEDLINE/PubMed
spelling pubmed-77591252020-12-28 Comparison of SARS-CoV-2 IgM and IgG seroconversion profiles among hospitalized patients in two US cities Orner, Erika P Rodgers, Mary A Hock, Karl Tang, Mei San Taylor, Russell Gardiner, Mary Olivo, Ana Fox, Amy Prostko, John Cloherty, Gavin Farnsworth, Christopher W. Diagn Microbiol Infect Dis Article The clinical and public health utility of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) serologic testing requires a better understanding of the dynamics of the humoral response to infection. To track seroconversion of IgG and IgM antibodies in patients with SARS-CoV-2 infection and its association with patient and clinical factors and outcomes. Residual patient specimens were analyzed on the Abbott ARCHITECT i2000 instrument using the Abbott SARS-CoV-2 IgG assay and prototype SARS-CoV-2 IgM assay. Age, sex, comorbidities, symptom onset date, mortality, and specimen collection date were obtained from electronic medical records. Three hundred fifty-nine longitudinal samples were collected from 89 hospitalized patients 0 to 82 days postsymptom onset. Of all, 51.7% of the patients developed IgG and IgM antibodies simultaneously; 32.8% seroconverted for IgM before IgG. On average, patients seroconverted for IgG by 8 days and for IgM by 7 days postsymptom onset. All patients achieved IgG seropositivity by 19 days and IgM seropositivity by 17 days. Median time to IgG and IgM seroconversion was prolonged and initial levels of IgG were lower in immunocompromised patients and patients <65 years of age compared to immune competent patients and those ≥65 years of age. Immunocompromised patients also had persistently lower levels of IgM that peaked on day 17.6 and decreased thereafter compared to immune competent patients. IgM seroconversion in patients who died reached significantly higher levels later after symptom onset than in those who recovered. SARS-CoV-2 infected patients have similar time to seroconversion for IgG and IgM. However, differences in immune status and age alter time to seroconversion. These results may help guide serologic testing application in COVID-19 management. Elsevier Inc. 2021-04 2020-12-24 /pmc/articles/PMC7759125/ /pubmed/33388575 http://dx.doi.org/10.1016/j.diagmicrobio.2020.115300 Text en © 2020 Elsevier Inc. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
spellingShingle Article
Orner, Erika P
Rodgers, Mary A
Hock, Karl
Tang, Mei San
Taylor, Russell
Gardiner, Mary
Olivo, Ana
Fox, Amy
Prostko, John
Cloherty, Gavin
Farnsworth, Christopher W.
Comparison of SARS-CoV-2 IgM and IgG seroconversion profiles among hospitalized patients in two US cities
title Comparison of SARS-CoV-2 IgM and IgG seroconversion profiles among hospitalized patients in two US cities
title_full Comparison of SARS-CoV-2 IgM and IgG seroconversion profiles among hospitalized patients in two US cities
title_fullStr Comparison of SARS-CoV-2 IgM and IgG seroconversion profiles among hospitalized patients in two US cities
title_full_unstemmed Comparison of SARS-CoV-2 IgM and IgG seroconversion profiles among hospitalized patients in two US cities
title_short Comparison of SARS-CoV-2 IgM and IgG seroconversion profiles among hospitalized patients in two US cities
title_sort comparison of sars-cov-2 igm and igg seroconversion profiles among hospitalized patients in two us cities
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7759125/
https://www.ncbi.nlm.nih.gov/pubmed/33388575
http://dx.doi.org/10.1016/j.diagmicrobio.2020.115300
work_keys_str_mv AT ornererikap comparisonofsarscov2igmandiggseroconversionprofilesamonghospitalizedpatientsintwouscities
AT rodgersmarya comparisonofsarscov2igmandiggseroconversionprofilesamonghospitalizedpatientsintwouscities
AT hockkarl comparisonofsarscov2igmandiggseroconversionprofilesamonghospitalizedpatientsintwouscities
AT tangmeisan comparisonofsarscov2igmandiggseroconversionprofilesamonghospitalizedpatientsintwouscities
AT taylorrussell comparisonofsarscov2igmandiggseroconversionprofilesamonghospitalizedpatientsintwouscities
AT gardinermary comparisonofsarscov2igmandiggseroconversionprofilesamonghospitalizedpatientsintwouscities
AT olivoana comparisonofsarscov2igmandiggseroconversionprofilesamonghospitalizedpatientsintwouscities
AT foxamy comparisonofsarscov2igmandiggseroconversionprofilesamonghospitalizedpatientsintwouscities
AT prostkojohn comparisonofsarscov2igmandiggseroconversionprofilesamonghospitalizedpatientsintwouscities
AT clohertygavin comparisonofsarscov2igmandiggseroconversionprofilesamonghospitalizedpatientsintwouscities
AT farnsworthchristopherw comparisonofsarscov2igmandiggseroconversionprofilesamonghospitalizedpatientsintwouscities